ADDvise Group publishes bond prospectus and applies for listing of its bonds on Nasdaq Stockholm

20-12-2021   Regulatory press release

ADDvise Group AB (publ) issued on 5 November 2021 a senior secured bond loan of SEK 250,000,000 within a total framework amount of SEK 500,000,000 on the Swedish bond market. The bonds carry a floating rate interest of STIBOR 3m + 7.25 per cent per annum (corresponding to a yield of approximately 6.6%) and matures 21 May 2024.

The company has applied for listing of the bonds on the corporate bond list at Nasdaq Stockholm. The bonds will be admitted to trading on or about 22 December 2021.  

In connection with this the company has prepared a prospectus. The prospectus has been approved by the Swedish Financial Supervisory Authority. The Prospectus will be available on the Financial Supervisory Authority's website (www.fi.se) and on the Company's website (www.addvisegroup.com).

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71

rikard.akhtarzand@addvisegroup.se

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

ADDvise acquires CliniChain Holding B.V.

Regulatory

ADDvise Group AB has today entered into a share purchase agreement with the owners of CliniChain Holding B.V. (“CliniChain”) regarding the acquisition of all the outstanding shares of CliniChain in accordance with the letter of intent communicated via a press release dated September 6, 2022. Closing of the acquisition takes place no later than December…

ADDvise receives order worth USD 1.7 million

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from BioGeneric Pharma, a leading factory in biotechnology based in Cairo, Egypt. The order is worth approximately USD 1.7 million. The order is an add-on-project in the ongoing project between the parties regarding design, supply, and commissioning of clean room environment to be used…

ADDvise Group successfully places subsequent senior secured bonds of SEK 150 million at par

Regulatory

ADDvise Group AB (publ) ("ADDvise" or the "Company") announces today that the Company has successfully placed a subsequent senior secured bond issue (the “Subsequent Bond Issue") in an amount of SEK 150 million under the Company’s existing senior secured bond framework with ISIN SE0015222088. Following completion of the Subsequent Bond Issue, the outstanding amount under…